COMMUNIQUÉS West-GlobeNewswire

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
06/08/2026
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc [...]
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
06/08/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; [...]
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable [...]
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
06/08/2026
ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast [...]
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to [...]
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
06/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
06/08/2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial design to characterize [...]
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
06/08/2026
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved Targeted Therapy to [...]
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
06/08/2026
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study builds on [...]
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
06/08/2026
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed [...]
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
06/08/2026
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46 th Annual Growth Conference on Tuesday, [...]
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
06/08/2026
TransCon ® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growth TransCon CNP monotherapy Week 104 data from the [...]
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
06/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
VivoSim Provides Financial and Listing Compliance Update
06/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety [...]
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
06/08/2026
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual [...]
Medecision Earns “Innovators” Distinction in Frost & Sullivan’s 2026 Frost Radar™ Report
06/08/2026
Recognition by the global analyst team in the U.S. Population Health Management category further validates Medecision’s unified data platform strategy KING OF PRUSSIA, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Medecision, [...]
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter [...]
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
06/08/2026
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and [...]

Pages